Clinical classification of pulmonary hypertension.
暂无分享,去创建一个
R. Speich | S. Rich | A. Fishman | D. Langleben | M. Beghetti | A P Fishman | D. Lebrec | S. Gibbs | G. Domenighetti | N. Galiè | G. Simonneau | Lewis J. Rubin | W. Seeger
[1] M. Humbert,et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. , 1998, AJR. American journal of roentgenology.
[2] S. Hodge,et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives , 2002, European Respiratory Journal.
[3] R. Barst,et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. , 2002, The Journal of rheumatology.
[4] J Benichou,et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.
[5] D. Schraufnagel,et al. Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. , 1996, The European respiratory journal.
[6] M. Humbert,et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. , 2002, Radiology.
[7] J. Edwards,et al. The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.
[8] G. Maislin,et al. Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.
[9] E. Braunwald,et al. FAMILIAL PULMONARY HYPERTENSION. , 1963, The New England journal of medicine.
[10] R. Escamilla,et al. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. , 1995, The European respiratory journal.
[11] R. Abbate,et al. Pulmonary hypertension associated with long-standing thrombocytosis. , 1991, Chest.
[12] L. Sharples,et al. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.
[13] M. Humbert,et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.
[14] R. Barst,et al. Familial pulmonary hypertension: immunogenetic findings in four Caucasian kindreds. , 1992, The American review of respiratory disease.
[15] K. Peterson,et al. Modifications of techniques and early results of pulmonary thromboendarterectomy for chronic pulmonary embolism. , 1987, The Journal of thoracic and cardiovascular surgery.
[16] E. Shinebourne,et al. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. , 1986, British heart journal.
[17] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[18] J. Mandel,et al. Pulmonary veno-occlusive disease. , 2000, American journal of respiratory and critical care medicine.
[19] Wagenvoort Ca. The pathology of primary pulmonary hypertension. , 1970 .
[20] M. Humbert,et al. Severe pulmonary hypertension in histiocytosis X. , 2000, American journal of respiratory and critical care medicine.
[21] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[22] M. Humbert,et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis , 2002, European Respiratory Journal.
[23] M. Gladwin,et al. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. , 2003, American journal of respiratory and critical care medicine.
[24] P. Dartevelle,et al. [Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications]. , 1994, Archives des maladies du coeur et des vaisseaux.
[25] M. Gladwin,et al. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. , 2001, American journal of respiratory and critical care medicine.
[26] D. Dresdale,et al. Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.
[27] A. Fishman. Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.
[28] P. Dartevelle,et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] A. Fishman. Dietary Pulmonary Hypertension , 1974, Circulation research.
[30] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[31] W. Auger,et al. Chronic major-vessel thromboembolic pulmonary hypertension. , 1990, Circulation.
[32] J. R. Kuipers,et al. Familial pulmonary veno-occlusive disease: a case report. , 1977, Thorax.
[33] M. Humbert,et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.
[34] M. Humbert,et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study , 1999 .
[35] R. Sapru,et al. Pulmonary hypertension in patients with pulmonary arteriovenous fistulae. , 1969, British heart journal.
[36] Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[37] P. Thistlethwaite,et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. , 2003, The Annals of thoracic surgery.
[38] E. Beutler,et al. Pulmonary Hypertension Developing after Alglucerase Therapy in Two Patients with Type 1 Gaucher Disease Complicated by the Hepatopulmonary Syndrome , 1996, Annals of Internal Medicine.
[39] M. Humbert,et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.
[40] N. Voelkel,et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.
[41] T. Takemura,et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. , 1992, Human pathology.
[42] O. Castro,et al. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.
[43] P. Dartevelle,et al. Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. , 1995, Chest.
[44] E. Ruchelli,et al. Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? , 1994, Archives of pathology & laboratory medicine.
[45] C. Pizzo,et al. Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. , 1980, Pediatrics.
[46] P. Wood. The Eisenmenger Syndrome , 1958 .
[47] L. Ackerson,et al. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. , 1996, American journal of respiratory and critical care medicine.
[48] E. Weitzenblum,et al. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. , 2015, The American review of respiratory disease.
[49] Yuan-Tsong Chen,et al. Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. , 1995, American journal of human genetics.
[50] John Arul Phillips,et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. , 2001, The New England journal of medicine.
[51] M. Humbert,et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.
[52] R. Barst,et al. Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.
[53] F. Basset,et al. Chronic cor pulmonale in pulmonary sarcoidosis. , 1978, Thorax.
[54] P. Presbitero,et al. Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.
[55] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.
[56] M. Humbert,et al. Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.
[57] H. Winer-Muram,et al. Pulmonary capillary hemangiomatosis: a clinicopathologic review. , 1994, The Annals of thoracic surgery.
[58] G. Garcia-Manero,et al. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases , 1999, American journal of hematology.
[59] S. Chuncharunee,et al. Pulmonary Arterial Hypertension in Previously Splenectomized Patients with β-Thalassemic Disorders , 2003 .
[60] J. Morse. Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension. , 2002, Chest.
[61] T. De,et al. Parenteral nutrition before gastrointestinal surgery. , 1982 .
[62] H. Ichinose,et al. Pulmonary veno-occlusive disease: Report of a case with pseudoangiomatous features , 1977 .
[63] R. Spellberg,et al. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. , 1993, Chest.
[64] J. Rouleau,et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.
[65] M. Humbert,et al. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). , 1998, Chest.
[66] D L Buschman,et al. Pulmonary histiocytosis X: comparison of radiographic and CT findings. , 1989, Radiology.
[67] R. R. Wolfe,et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. , 1993, Circulation.
[68] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[69] F. Harrell,et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.
[70] O. Castro,et al. Pulmonary hypertension in sickle cell disease. , 1994, The American journal of cardiology.
[71] A. Oberg,et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. , 2001, Chest.
[72] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[73] E. Trell,et al. Familial pulmonary hypertension and multiple abnormalities of large systemic arteries in Osler's disease. , 1972, The American journal of medicine.
[74] K. Peterson,et al. Pulmonary vascular occlusion and fibrosing mediastinitis. , 1986, Chest.
[75] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[76] J. Spijker,et al. Capillary haemangiomatosis of the lungs , 1978, Histopathology.
[77] M. Keszler,et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. , 2000, The New England journal of medicine.
[78] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.
[79] J. Newman,et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. , 2003, American journal of respiratory and critical care medicine.
[80] S. Schneeweiss,et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. , 2000, Chest.